This site and its domain are for sale. Email the owner if you want to talk about it.

bariatricalt.com

ESG vs Gastric Sleeve: Smaller Procedure, Smaller Result?

One procedure removes part of the stomach and the other stitches it, and only one of them has been properly measured against the other.

Two simplified stomach diagrams side by side, one with a resected portion removed and one with rows of sutures forming a narrow tube.

There are two ways to turn a human stomach into a narrow tube, and the main difference between them is whether any of the stomach gets thrown away. A laparoscopic sleeve gastrectomy, which a seven-year study of revision operations calls “currently the most performed bariatric procedure worldwide,” cuts part of the stomach out. Endoscopic sleeve gastroplasty, or ESG, goes in through the mouth with a suturing device and stitches the stomach into a tube. A qualitative narrative review of ESG describes this as a way “to create a tubular gastric sleeve without resection, preserving native anatomy.”

On the evidence that exists, the plain answer to esg vs gastric sleeve is that the sleeve takes off more weight and ESG gets people back on their feet faster. A retrospective study of 70 ESG patients and 70 sleeve patients in Lebanon found the sleeve produced greater total body weight loss at both 6 and 12 months. One review puts ESG recovery at 2 to 3 days versus 2 to 6 weeks for the sleeve, and a network meta-analysis found ESG had much lower odds of new reflux (an odds ratio of 0.08). What does not exist, among the studies here, is a large randomized trial putting the two side by side. That is the interesting part.

ESG vs gastric sleeve: what the matched data shows

Here is the comparative evidence, such as it is. The Lebanese study took its ESG patients from Fouad Khoury Hospital and its sleeve patients from Trad Hospital, with procedures done between September 2021 and March 2023. Two hospitals, two groups, one spreadsheet. The sleeve won on weight loss at both time points.

The bigger dataset is the MBSAQIP database. An analysis of its 2023 data covered 115,476 patients, of whom 114,967 had a sleeve and 509 had ESG. That is a lot of sleeves. (Statistically 509 is a perfectly real number; it is just a lonely one.) That analysis found no clinically meaningful improvement in obesity-related conditions among the ESG patients at six months. The MERIT randomized trial, by contrast, reported that 80% of ESG participants improved at least one metabolic comorbidity at 52 weeks.

So which is it? One reading is that ESG does less for the metabolic stuff once it leaves the tidy world of a trial. The other reading is that six months is not 52 weeks, and the people who choose a stitched tube at a surgical center may simply start out different from the people who choose a cut one, with less to fix. The facts here do not say which reading is right.

The long numbers are lopsided too. A review of very long-term outcomes put the sleeve’s weighted mean total weight loss at 24.4% at 10 years. ESG’s best randomized number is from MERIT: 13.6% total body weight loss and 49.2% excess weight loss at 52 weeks, with 68% of participants keeping at least 25% excess weight loss at 104 weeks. But MERIT enrolled people with class 1 and 2 obesity, and a ten-year number against a one-year number is sort of apples against a younger, smaller apple. Smaller procedure, smaller result, probably. How much smaller is not settled.

Why ESG’s best trial was against a diet

Here is the chain of who gets paid for what. Start with an endoscopist who has a procedure that removes nothing. To be taken seriously she needs a randomized trial, and the cleanest one she can run is ESG plus lifestyle changes against lifestyle changes alone, because nobody has to flip a coin over whether to keep part of their stomach. MERIT did basically that, and ESG won easily: 13.6% total body weight loss against 0.8% for the controls.

Next link: the payer. A cost-effectiveness analysis built on MERIT data, from a US commercial payer perspective, found ESG “dominated lifestyle modification alone over longer time horizons” and cost $23,432 per quality-adjusted life year over 5 years. (A quality-adjusted life year is the health economist’s unit of one good year, which is a strange thing to have a unit for, but here we are.) Then a Markov model compared ESG to the drug: semaglutide’s annual cost of about $13,618 would need to fall roughly threefold, to about $3,591, to be cost-competitive with ESG over 5 years for class 2 obesity.

So ESG has been priced against a diet and priced against a drug. Among the facts here, it has not been priced against the sleeve, and neither procedure comes with a dollar figure attached. The invented version of the meeting goes: “Hey guys, it beats the diet by about thirteen points.” “Great. Against the sleeve?” “Different department.”

Look, each party is acting sensibly from where it stands. The endoscopist ran the trial she could actually run. The payer asked the question payers ask, which is whether a thing is worth buying compared to not buying it. The surgeons have 114,967 sleeves a year in one database alone and no special reason to randomize patients away from an operation that works. Also, as in most of medicine, the line between the doctors who study a new procedure, the doctors who teach it, and the doctors who do a great many of them is blurry, in the way the line between a conference and a nice week somewhere warm is blurry.

And so the chain arrives at a place nobody intended. The comparison that patients type into a search box is the one the evidence machine was least built to produce.

This is invented, but consider what the settling trial would need. It needs hundreds of volunteers who are honestly indifferent between losing part of their stomach and keeping all of it, who are equally content with 2 to 3 days of recovery or 2 to 6 weeks, who will let a coin decide, who will come back every year for a decade, and who will not, at any point, look up the other procedure. Such a person exists in roughly the way a frictionless market exists. You would need several hundred of them. They would all need to live near the same two hospitals.

Recovery: days against weeks

This is where the smaller procedure is actually smaller. ESG is usually done under general anesthesia, and one recovery guide lays out the eating plan afterward: clear, non-carbonated liquids and vitamins for days 1 and 2, high-protein, low-calorie full liquids low in fat and sugar for days 3 to 7, then soft and pureed foods for weeks 2 and 3. It’s fine. It is a lot of broth. The headline figure, from a review on the future of restrictive surgery, is 2 to 3 days of recovery for ESG against 2 to 6 weeks for the sleeve.

The stitches are not purely mechanical either. A MERIT sub-study found ESG slowed stomach emptying (a half-time of 170.8 minutes against 87.5 for controls at 3 months, and 133.4 against 87.6 at 12 months) and raised fasting GLP-1 by 51% at 12 months. So the tube does something to the hormones as well as the volume, I guess, which is more than the word “stitches” suggests.

It can also go wrong in its own way. Across 4,350 ESG procedures at six expert centers, 9 patients had abdominal pain lasting more than 15 days, an incidence of 0.21%. The most common suspected cause, in 55.6% of them, was “excessive plication-related tension,” which is in some sense the procedure working slightly too hard. (I am not a gastroenterologist; my qualification here is reading tables with confidence I have not earned.)

Revisions, reflux and what happens later

In a 6-year cohort of 1,377 ESG patients, 5.7% needed a revision. In the Polish BARI-10-POL study, where 317 of 485 patients had a sleeve, 24.3% of sleeve patients needed a revision over 10 years. Those are different studies with different lengths and different patients, so the gap is suggestive and nothing more. Reflux tilts the same way: the network meta-analysis favored ESG on new reflux, and the Oseberg trial found more acid reflux after the sleeve than after bypass (which is another article’s subject).

There is also a quieter feature of keeping everything. The narrative review notes ESG can serve as a revision for weight regain after earlier non-resective procedures, because the preserved anatomy can be modified safely. A stomach that has not been cut still has all its options.

So: two ways to make a stomach into a tube, and they differ in whether any of it is thrown away and in how carefully anyone has measured the difference. One has a decade of numbers. The other has a trial against a diet and a model against a drug.

So the people choosing between them are the trial.

Sources

  1. Long-term outcomes of metabolic bariatric surgery: a 10-Year multicenter retrospective study in Poland (BARI-10-POL)
  2. Endoscopic Sleeve Gastroplasty: A Qualitative Narrative Review of Outcomes, Safety, and Clinical Applications
  3. Randomized Controlled Trial Based US Commercial Payor Cost-Effectiveness Analysis of Endoscopic Sleeve Gastroplasty Versus Lifestyle Modification Alone for Adults With Class I/II Obesity
  4. IBCOx-12 The Endoscopic Sleeve Gastroplasty Produces Durable Physiologic Changes: Results from a Randomized US Clinical Trial
  5. Endoscopic Sleeve Gastroplasty: 6-Year Outcomes in 1,377 Patients
  6. Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
  7. Improvement of Obesity-Related Comorbidities After Bariatric Procedures: A Network Meta-Analysis of Endoscopic Versus Surgical Interventions
  8. A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
  9. Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy: A Comparison in Effectiveness and Safety Profile
  10. Persistent Abdominal Pain After Endoscopic Sleeve Gastroplasty: A Multicenter Case Series and Hypothesis-Generating Management Framework
  11. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
  12. ESG recovery timeline and diet guide | What to expect after Endoscopic Sleeve Gastroplasty
  13. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss
  14. Six-month comparative outcomes of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: an MBSAQIP analysis
  15. Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
  16. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial

Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.

Read next